Stock Taper
SCREENER COMPARE ANY 2 STOCKS
FHTX
FOGHORN THERAPEUTICS INC.
NASDAQ
$6.00
▼ DOWN 3.54% (-0.22)

KEY STATISTICS

Market Cap$352.28 M
52w High$7.61
52w Low$3.27
Dividend Yield—
Frequency—
P/E-6.12
Volume370.71K
Shares Out.58.71M

COMPANY

LEADERSHIP

Adrian H. Gottschalk
CHIEF EXECUTIVE
Adrian H. Gottschalk

COMPENSATION 2026

Salary$638,000
Stock Awards$0
Incentive Plan Pay$385,990
All Other Comp.$3,000
Total$2,361,027

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 23, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
106

PRICE TARGET

Target High$20.00
Target Low$9.00
Target Median$12.00
Target Consensus$13.86

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$7.09M
NOV
4
WED

PRICE

$6.00 ▼ DOWN 3.54% (−$0.22)
$6.00$6.08$6.159:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM6.00

About Foghorn Therapeutics Inc.

https://foghorntx.com ↗

Foghorn Therapeutics Inc. is a Cambridge-based biotech developing targeted cancer therapies using its Gene Traffic Control platform, with programs against BRG1, BRM, BRD9, and ARID1B, and collaborations with Merck and Loxo Oncology.

INDUSTRY

Biotechnology

A PRODUCT FOGHORN THERAPEUTICS INC. IS KNOWN FOR

FHD-909
FHD-909

A first-in-class oral small molecule inhibiting SMARCA2, in Phase 1 trials for SMARCA4-mutant cancers like NSCLC, developed with Eli Lilly.

COMPETITORS

COMPETITOR
ARVN COMPARE
CCCC COMPARE
IMTX COMPARE
KYMR COMPARE
NRIX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
55
LISTED HERE
8
RANKED BY POSITION SIZE
VTS.AX
0.00% · 1.0M
IWM
0.01% · 884.9K
ZPRR.DE
0.01% · 50.2K
OMFS
0.11% · 49.4K
XRS2.DE
0.01% · 33.4K
RSSL
0.01% · 17.3K
BIB
0.01% · 2.1K
FSEG
0.08% · 826

INSTITUTIONAL OWNERSHIP

SHARES OWNED
72.96%
HOLDERS
124
TOP 12 OF 124 · RANKED BY POSITION SIZE
Flagship Pioneering Inc.
12.7M sh · $68.44M
Fmr LLC
6.0M sh · $28.91M
Bvf Inc/Il
5.8M sh · $27.92M
Deerfield Management Company, L.P. (Series C)
4.4M sh · $21.01M
Raymond James Financial Inc
2.6M sh · $12.44M
Blackrock, Inc.
2.4M sh · $11.3M
Raymond James & Associates
2.3M sh · $21.39M
Vanguard Group Inc
1.9M sh · $10.42M
Euclidean Capital LLC
1.6M sh · $7.52M
Blackrock Inc.
1.5M sh · $8.89M
Geode Capital Management, LLC
848.2K sh · $4.06M
Siren, L.L.C.
720.7K sh · $3.45M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR
Gallagher Neil
Purchase · 28.0K shares
2026-06-24
★
DIRECTOR
Cole Douglas G.
Purchase · 28.0K shares
2026-06-24
★
DIRECTOR
PARSHALL B LYNNE
Purchase · 28.0K shares
2026-06-24
★
DIRECTOR
Duty Stuart
Purchase · 28.0K shares
2026-06-24

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
OUTPERFORM 1
3 GRADES IN THE LAST 12 MONTHS
Wedbush OUTPERFORM HC Wainwright & Co. BUY Jefferies BUY

SECTORS PEERS

PEERPRICE
ASMB$34.07COMPARE
ZURA$5.72COMPARE
ARCT$15.19COMPARE
ENTA$13.60COMPARE
SGMT$10.55COMPARE
VNDA$5.29COMPARE
TRDA$7.00COMPARE
PYXS$3.23COMPARE